Cardio Diagnostics Holdings Inc
CDIO
View Detailed Chart
1.290USD
+0.240+22.86%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.28MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+22.86%
5 Days
-14.57%
1 Month
-56.35%
6 Months
-67.26%
Year to Date
-52.40%
1 Year
-90.52%
View Detailed Chart
TradingKey Stock Score of Cardio Diagnostics Holdings Inc
Currency: USD Updated: 2026-02-06Key Insights
Cardio Diagnostics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 232 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 60.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardio Diagnostics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cardio Diagnostics Holdings Inc Highlights
StrengthsRisks
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 3572.63% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.89K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 34.89K.
Overvalued
The company’s latest PE is -0.40, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 24.12K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
60.000
Target Price
+1227.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cardio Diagnostics Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardio Diagnostics Holdings Inc Info
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Ticker SymbolCDIO
CompanyCardio Diagnostics Holdings Inc
CEODogan (Meeshanthini V)
Website
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69174.200
-795.930 (-1.14%)
282.580
+22.390 (+8.61%)
2052.400
+0.670 (+0.03%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
